论文部分内容阅读
目的:探讨瑞舒伐他汀对急性冠脉综合征患者颈动脉斑块的影响及机制。方法:对70例急性冠脉综合征患者常规治疗外,加用瑞舒伐他汀10 m g,每晚一次。治疗6个月后测血脂及超敏C反应蛋白(hs-CRP)的水平,采用彩色多普勒测定颈动脉内膜的厚度及颈动脉斑块治疗前后的变化。结果:70例急性冠脉综合征患者瑞舒伐他汀治疗后6个月,总胆固醇、低密度脂蛋白胆固醇、hs-CRP显著低于治疗前水平(P<0.001~0.01)。双侧颈动脉内膜厚度及颈动脉斑块缩小程度,与治疗前比较有显著差异(P<0.01)。结论:瑞舒伐他汀通过降低血脂、降低hs-CRP水平,稳定急性冠脉综合征患者颈动脉斑块。
Objective: To investigate the effect and mechanism of rosuvastatin on carotid artery plaque in patients with acute coronary syndrome. Methods: Seventy patients with acute coronary syndrome were treated with rosuvastatin 10 m g once a night. Serum lipids and hs-CRP levels were measured 6 months after treatment. The thickness of carotid intima and the changes of carotid artery plaque before and after treatment were measured by color Doppler. Results: The total cholesterol, low density lipoprotein cholesterol and hs-CRP in 70 patients with acute coronary syndrome were significantly lower than those before treatment (P <0.001 ~ 0.01) 6 months after treatment with rosuvastatin. Bilateral carotid intima-media thickness and carotid plaque size reduction, compared with before treatment were significantly different (P <0.01). Conclusion: Rosuvastatin can stabilize the carotid plaque in patients with acute coronary syndrome by lowering blood lipids and decreasing the level of hs-CRP.